Capricor Therapeutics
CAPR
Market cap $314M

6.88 USD

-0.28

3.91%

At close Jul 18, 4:00 PM EDT

After hours

6.92

+0.04

0.58%

1 day

-3.91%

5 days

-6.90%

1 month

-42.38%

3 months

-42.28%

6 months

-51.07%

Year to date

-54.01%

1 year

47.01%

5 years

9.21%

10 years

-86.21%

About: Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Employees: 160

Healthcare Biotechnology

0

Funds holding %

of 7,321 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

92% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 24

74% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 19

47% more call options, than puts

Call options by funds: $17M | Put options by funds: $11.6M

12% more funds holding

Funds holding: 108 [Q4 2024] → 121 (+13) [Q1 2025]

2.02% more ownership

Funds ownership: 38.11% [Q4 2024] → 40.13% (+2.02%) [Q1 2025]

27% less capital invested

Capital invested by funds: $239M [Q4 2024] → $174M (-$65.1M) [Q1 2025]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 0 (-1) [Q1 2025]

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$12

74%

upside

Avg. target

$23

234%

upside

High target

$30

336%

upside

6 analyst ratings

6 positive

100%

0 neutral

0%

0 negative

0%

Roth Capital Boobalan Pachaiyappan	74%upside $12	Buy Maintained	14 Jul 2025
HC Wainwright & Co. Joseph Pantginis	249%upside $24	Buy Maintained	11 Jul 2025
B. Riley Securities Madison El-Saadi	205%upside $21	Buy Initiated	26 Jun 2025
Jones Trading Catherine Novack	322%upside $29	Buy Maintained	25 Jun 2025
Oppenheimer Leland Gershell	220%upside $22	Outperform Maintained	23 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 37 articles about CAPR published over the past 30 days

CAPRICOR ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Capricor (CAPR) To Contact Him Directly To Discuss Their Options

CAPRICOR ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. and Encourages Investors to Contact the Firm

CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or “the Company”) (NASDAQ: CAPR) and certain of its officers.

CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Capricor To Contact Him Directly To Discuss Their Options

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

CAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) INVESTOR ALERT: Investors With Large Losses in Capricor Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

CAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) INVESTOR ALERT Investors With Large Losses in Capricor Therapeutics, Inc. Should Contact Bernstein Liebhard LLP

CAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) INVESTOR ALERT: Investors With Large Losses in Capricor Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. (CAPR)

NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of all persons or entities who purchased or otherwise acquired Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) securities between October 9, 2024 and July 10, 2025, both dates inclusive (the “Class Period”).

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. (CAPR)

CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)---- $CAPR--CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.

CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Shareholder Alert: Robbins LLP Informs Investors of the Capricor Therapeutics, Inc. Class Action

SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between October 9, 2024 and July 10, 2025. Capricor is a clinical-stage biotechnology company that engages in the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.

Shareholder Alert: Robbins LLP Informs Investors of the Capricor Therapeutics, Inc. Class Action

INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Capricor Therapeutics, Inc. (CAPR) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

ATLANTA, July 17, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information concerning Capricor's four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel.

INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Capricor Therapeutics, Inc. (CAPR) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Capricor Therapeutics, Inc. Securities and Sets a Lead Plaintiff Deadline of September 15, 2025

NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, both dates inclusive. You are hereby notified that the class action lawsuit Hau Xiang Leong v.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Capricor Therapeutics, Inc. Securities and Sets a Lead Plaintiff Deadline of September 15, 2025

BREAKING: Capricor Therapeutics Sued For Securities Fraud; Investors Should Contact Block & Leviton to Potentially Recover Losses

Block & Leviton announces that a securities fraud lawsuit has been filed against Capricor Therapeutics (Nasdaq: CAPR). Investors should contact the firm.

BREAKING: Capricor Therapeutics Sued For Securities Fraud; Investors Should Contact Block & Leviton to Potentially Recover Losses

See News Rankings

Charts implemented using Lightweight Charts™